Interestingly, a randomized controlled trial (RCT) reported that dapagliflozin monotherapy in T2DM patients was associated with a significant reduction in FGF21 levels, while no significant changes in placebo or dual therapy with dapagliflozin and omega-3 carboxylic acids groups were observed [57]. This evidence concerns the gene FGF21 and type 2 diabetes mellitus.